# Resource Summary Report

Generated by NIF on Apr 22, 2025

## miRTarVisPlus

RRID:SCR_017103
Type: Tool

### Proper Citation

miRTarVisPlus (RRID:SCR_017103)

### Resource Information

**URL:** http://sehilyi.com/mirtarvisplus/

**Proper Citation:** miRTarVisPlus (RRID:SCR_017103)

**Description:** Web based interactive visual analytics tool for miRNA target predictions and integrative analyses of multiple prediction results. Used for sequence based miRNA target prediction by exploiting miRNA-mRNA expression profile data.

**Abbreviations:** miRTarVis+

**Synonyms:** mirtarvisplus

**Resource Type:** data access protocol, service resource, data analysis service, analysis service resource, web service, software resource, production service resource

**Defining Citation:** PMID:28600227

**Keywords:** interactive, visual, analytical, miRNA, target, prediction, analysis, mRNA, expression, data

**Funding:** National Research Foundation of Korea ;
Hankuk University of Foreign Studies Research Fund

**Availability:** Free, Freely available

**Resource Name:** miRTarVisPlus

**Resource ID:** SCR_017103

**Alternate URLs:** http://hcil.snu.ac.kr/research/mirtarvisplus

**Record Creation Time:** 20220129T080333+0000

**Record Last Update:** 20250421T054152+0000

## Ratings and Alerts

No rating or validation information has been found for miRTarVisPlus.

No alerts have been found for miRTarVisPlus.

## Data and Source Information

**Source:** SciCrunch Registry

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at NIF.

Awoyemi T, et al. (2024) MicroRNA analysis of medium/large placenta extracellular vesicles in normal and preeclampsia pregnancies. Frontiers in cardiovascular medicine, 11, 1371168.

Bi S, et al. (2020) Bioinformatics analysis of key genes and miRNAs associated with Stanford type A aortic dissection. Journal of thoracic disease, 12(9), 4842.

Yang L, et al. (2019) Clinical Features and MicroRNA Expression Patterns Between AML Patients With DNMT3A R882 and Frameshift Mutations. Frontiers in oncology, 9, 1133.